Erica Hong, Ph.D.

Technology Specialist - Boston

Erica Hong
Download Media Photo

Contact Information


6178327000 Download vCard

Erica Hong prosecutes U.S. and foreign patent applications in the biotechnology, chemical, and pharmaceutical fields. Dr. Hong also assists in client counseling and providing opinions regarding patent validity.

Dr. Hong has technical experience in genetics, cellular biology, biochemistry and biophysics.  During her graduate work at Yale University, she studied the signaling pathway of DNA damage checkpoint.  As a fellow of Leukemia and Lymphoma Society at Harvard Medical school, she studied the structure and dynamics of chromatin and heterochromatin. 

More ยป


  • Yale University, Ph.D., Molecular, Cellular, Developmental Biology
  • University of Southern California (USC), B.S., Biological Sciences



  • Abrams, T., Connor, A., Fanton, C., Cohen, S., Huber, T., Miller, K., Hong, E., Niu, X., Kline, J., Ison-Dugenny, M., Harris, S., Walker, D., Krauser, K., Galimi, F., Wang, Z., Ghoddusi, M., Mansfield, K., Lee-Hoeflich, S., Holash, J., Pryer, N., Kluwe, W., Ettenberg, S., Sellers, W., Lees, E., Kwon, P., Abraham, J., Schleyer, S. (2018) Potent preclinical antitumor activity of a novel anti-c-KIT antibody drug conjugate against mutant and wild type c-KIT positive solid tumors.  Clinical Cancer Research (Accepted)
  • Sun, X., Ponte, JF., Yoder, NC., Laleau, R., Coccia, J., Lanieri, L., Qiu, Q., Wu, R., Hong, E., Bogalhas, M., Wang, L., Dong, L., Setiady, Y., Maloney, EK., Ab, O., Zhang, X., Pinkas, J., Keating, TA., Chari, R., Erickson, HK., Lambert, JM. (2017) Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates. Bioconjug Chem. 28(5):1371-1381
  • Singh, R., Setiady, Y., Ponte, J., Kovtun, Y., Lai, K., Hong, E., Fishkin, N., Dong, L., Jones, G., Coccia, J., Lanieri, L., Veale, K., Costoplus, J., Skaletskaya, A., Gabriel, R., Salomon, P., Wu, R., Qiu, Q., Erickson, H., Lambert, J., Chari, R., Widdison, W. (2016) A new, triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells. Molecular Cancer Therapeutics 15(6):1311-20
  • Widdison, W., Ponte, J., Coccia, J., Qiu, Q., Lanieri, L., Setiady, Y., Dong, L., Skaletskaya, A., Hong, E., Wu, R., Fishkin, N., Kovtun, Y., Veale, K., Wilhelm, S., Audette, C., Costoplus, J., Chari, R. (2015) Development of anilino-maytansinoid ADCs that induce high levels of bystander killing. Bioconjugate Chemistry 18;26(11):2261-78
  • Hong, E., Erickson, H., Lutz, R., Whiteman, K., Jones, G., Kovtun, Y., Blanc, V., Lambert, J. (2015) Design of Coltuximab Ravtansine, a CD19-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies: structure-activity relationships and preclinical evaluation. Mol Pharm. 12(6):1703-16
  • Hong, E., Chari, R. (2015) Linker design for antibody-drug conjugates, Antibody-drug conjugates, the 21st century magic bullets for cancer. AAPS Advances in the Pharmaceutical Sciences Series 17:49